Recent Updates
Recently added Catalysts
QURE Negative Sentiment

UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th

Key Takeaway: A class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) by Bragar Eagel & Squire, P.C. for misleading investors. The lawsuit claims that during the specified Class Period, the company made materially false statements concerning its business and operations. Investors who acquired shares between September and October 2025 are urged to act before the April 13, 2026 deadline to apply as lead plaintiff. Significant concerns include unapproved study designs that may affect the Biologics License Application timeline.
Price reaction · baseline $16.89 (2026-04-01 close) · hit after-hours · 3 other QURE headline(s) in the window, move may be shared
day 0 close
+1.6%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against uniQure for misleading statements.
  • Claims regarding unapproved study designs affecting the BLA timeline.
  • Investors encouraged to contact law firm due to substantial losses.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+425%
120-day peak, hindsight
Typical move
5.1%
average across 6 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
rAAV2/5-PBGD vector dosage 1
Phase 1 · Acute Intermittent Porphyria

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
If you purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, both dates inclusive (the “Class Period”).
Investors have until April 13, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you purchased or otherwise acquired uniQure shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Frequently Asked Questions

What is the timeframe to join the uniQure lawsuit?

Investors have until April 13, 2026, to apply to be a lead plaintiff.

Who should contact Bragar Eagel & Squire?

Investors who acquired uniQure shares and suffered losses should contact them.

What allegations are made against uniQure?

The lawsuit claims uniQure made false statements and withheld material facts.

How can I get in touch with the law firm?

Contact Brandon Walker or Melissa Fortunato at (212) 355-4648 or via email.

Is there a fee to discuss my case with the firm?

There is no cost or obligation to discuss your case with Bragar Eagel & Squire.

Last updated: Apr 2, 2026